Protective Effects of Nanoparticle-Loaded Aliskiren on Cardiovascular System in Spontaneously Hypertensive Rats

Protective Effects of Nanoparticle-Loaded Aliskiren on Cardiovascular System in Spontaneously Hypertensive Rats

Aliskiren, a renin inhibitor, has been shown to have cardioprotective and blood pressure (BP) lowering effects. We aimed to determine the effects of nanoparticle-loaded aliskiren on BP, nitric oxide synthase activity (NOS) and structural alterations of the heart and aorta developed due to spontaneou...

Full description

Bibliographic Details
Main Authors:	Olga Pechanova, Andrej Barta, Martina Koneracka, Vlasta Zavisova, Martina Kubovcikova, Jana Klimentova, Jozef Tӧrӧk, Anna Zemancikova, Martina Cebova
Format:	Article
Language:	English
Published:	MDPI AG 2019-07-01
Series:	Molecules
Subjects:	hypertension renin aliskiren nitric oxide heart aorta vasoactivity collagen PLA nanoparticles
Online Access:	https://www.mdpi.com/1420-3049/24/15/2710

Similar Items

Aliskiren-Loaded Nanoparticles Downregulate (Pro)renin Receptor and ACE Gene Expression in the Heart of Spontaneously Hypertensive Rats: Effect on NADPH Oxidase
by: Andrej Barta, et al.
Published: (2024-01-01)

Aliskiren, Obat Antihipertensi Baru dengan Mekanisme Penghambat Renin
by: Diana Holidah
Published: (2011-12-01)

ALISKIREN (RENIN INHIBITOR) AS THE RECENT ANTIHYPERTENSIVE MODALITY
by: Luh Gde Primahatini Suaka Putri
Published: (2013-12-01)

Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension
by: Karl Andersen
Published: (2009-03-01)

Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy
by: Kalathil K Sureshkumar
Published: (2008-12-01)

Aliskiren: An orally active renin inhibitor
by: Pranay Wal, et al.
Published: (2011-01-01)

Antidepressant-like Effects of Renin Inhibitor Aliskiren in an Inflammatory Mouse Model of Depression
by: Sami I. Alzarea, et al.
Published: (2022-05-01)

Direct renin inhibitors aliskiren - possibilities correction cardiorenal syndrome
by: Irina Evgen'evna Chazova, et al.
Published: (2009-12-01)

Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease
by: Li Szu-yuan, et al.
Published: (2012-08-01)

The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction
by: Paolo Verdecchia, et al.
Published: (2008-10-01)

Direct renin inhibitor aliskiren in surgical treatment of nephrolithiasis
by: A.N., et al.
Published: (2013-03-01)

Anti-fibrotic effect of Aliskiren in rats with deoxycorticosterone induced myocardial fibrosis and its potential mechanism
by: Likun Ma, et al.
Published: (2012-05-01)

The results of the open observational, international, multicenter, prospective program to assess the efficacy, safety and tolerability of the first direct renin inhibitor RasilezR (aliskiren) in patients with arterial hypertension in ‘real-life’ clinical practice settings (DRIve)
by: I Ye Chazova
Published: (2014-09-01)

Aliskiren administration during early postnatal life sex-specifically alleviates hypertension programmed by maternal high fructose consumption
by: You-Lin Tain, et al.
Published: (2016-07-01)

Aliskiren and valsartan in combination is a promising therapy for hypertensive renal injury in rats
by: Hala Salah Abdel Kawy
Published: (2018-08-01)

COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option?
by: Selçuk Şen, et al.
Published: (2020-10-01)

Chronic L-Name-Treatment Produces Hypertension by Different Mechanisms in Peripheral Tissues and Brain: Role of Central eNOS
by: Olga Pechanova, et al.
Published: (2020-12-01)

Add-on aliskiren treatment can decrease blood pressure but requires attention to risks of renal impairment and hyperkalemia Chikushi Anti-Hypertension Trial-Rasilez® (CHAT-Ras)
by: Keisuke Okamura, et al.
Published: (2020-08-01)

Investigation renin inhibitor activity from flavonoids derivates by in silico study
by: Aprilita Rina Yanti Eff, et al.
Published: (2023-01-01)

Combined Therapy with Simvastatin- and Coenzyme-Q10-Loaded Nanoparticles Upregulates the Akt-eNOS Pathway in Experimental Metabolic Syndrome
by: Ezgi Şaman, et al.
Published: (2022-12-01)

Clinical and economic impact of aliskiren in uncontrolled hypertensive patients
by: Ezio Degli Esposti, et al.
Published: (2012-03-01)

Development and validation of an UV spectrophotometric method for the determination of aliskiren in tablets
by: Micheli Wrasse-Sangoi, et al.
Published: (2010-01-01)

Renin inhibitors are a new direction in the treatment of arterial hypertension
by: Yuriy Aleksandrovich Vasyuk, et al.
Published: (2010-09-01)

Renoprotective effect of aliskiren monotherapy and aliskiren−pentoxifylline combination in hypertensive-diabetic type 2 patients with diabetic nephropathy
by: Amin T. Hamed, et al.
Published: (2013-12-01)

Budget impact analysis of use of aliskiren in hypertension on the Italian Health Care System
by: Orietta Zaniolo, et al.
Published: (2009-03-01)

Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews
by: Qiyuan Zhao, et al.
Published: (2020-04-01)

Royal Jelly and Aliskiren mutually annul their protective effects against gentamicin-induced nephrotoxicity in rats
by: Mohd Alaraj
Published: (2020-12-01)

Aliskiren effect on non-alcoholic steatohepatitis in metabolic syndrome
by: F. N. Ramalho, et al.
Published: (2017-10-01)

The Anti-Inflammatory Effect of Different Doses of Aliskiren in Rat Models of Inflammation
by: Aziz TA, et al.
Published: (2020-07-01)

Aliskiren Attenuates the Inflammatory Response and Wound Healing Process in Diabetic Mice With Periodontal Disease
by: Sandra Helena Penha Oliveira, et al.
Published: (2019-07-01)

Aliskiren attenuates cardiac dysfunction by modulation of the mTOR and apoptosis pathways
by: Zhengbo Zhao, et al.
Published: (2020-01-01)

Comparative evaluation of aliskiren, ramipril, and losartan on psychomotor performance in healthy volunteers: A preliminary report
by: Ekta Arora, et al.
Published: (2014-01-01)

Different adaptive NO-dependent Mechanisms in Normal and Hypertensive Conditions
by: Michaela Kosutova, et al.
Published: (2019-04-01)

Effect of aliskiren, telmisartan and torsemide on cardiac dysfunction in l-nitro arginine methyl ester (l-NAME) induced hypertension in rats
by: Sawsan A. Sadek, et al.
Published: (2015-11-01)

Effects of Aliskiren, an RAAS inhibitor, on a carrageenan-induced pleurisy model of rats
by: YASIN BAYIR, et al.
Published: (2018-12-01)

The Potential Effects of Aliskiren on Atrial Remodeling Induced by Chronic Intermittent Hypoxia in Rats
by: Miao S, et al.
Published: (2020-09-01)

Beneficial Effects of Cornelian Cherries on Lipid Profile and NO/ROS Balance in Obese Zucker Rats: Comparison with CoQ10
by: Ezgi Dayar, et al.
Published: (2020-04-01)

Antioxidant Effect of <i>Lonicera caerulea</i> L. in the Cardiovascular System of Obese Zucker Rats
by: Ezgi Dayar, et al.
Published: (2021-07-01)

COMBINATION OF DIRECT RENNIN INHIBITOR - ALISKIREN, ANGIOTENSIN II RECEPTOR BLOCKER - VALSARTAN, AND CALCIUM CHANNEL BLOCKER - AMLODIPINE, IN THERAPY OF HYPERTENSIVE PATIENT WITH GOUT (CASE REPORT)
by: O. V. Dralova, et al.
Published: (2016-01-01)

Aliskiren Hemifumarate Proliposomes for Improved Oral Drug Delivery: Formulation Development, In Vitro and In Vivo Permeability Testing
by: Priyanka Kunamaneni, et al.
Published: (2022-07-01)